Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions
세계의 재발 및 전이 부문을 중심으로 한 암 치료제 시장 규모는 2024년 1,161억 달러로 평가되었습니다. 예측 기간 중에는 7.7%의 연평균 복합 성장률(CAGR)로 성장할 전망이고 2029년 말에는 1,680억 달러에 달할 것으로 예상되고 있습니다.
폐암 치료제 부문은 2024년 162억 달러로 평가되었습니다. 12.4%의 연평균 복합 성장률(CAGR)로 성장할 것으로 전망되고 2029년에는 290억 달러에 이를 것으로 예측됩니다. 로 예측됩니다. 유방암 치료제 부문은 2024년 137억 달러에 이르렀습니다. CAGR 11.4%로 성장할 것으로 예상되며 2029년에는 236억 달러에 이를 것으로 예측됩니다.
본 보고서에서는 세계의 재발 및 전이 부문을 중심으로 한 암 치료제 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법규제 환경, 신기술 및 기술 개발 동향, 시장 규모 추이와 예측, 각종 구분, 지역별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.
목차
제1장 주요 요약
제2장 시장 개요
- 개요
- 전이성 또는 재발성 암 치료의 유형
- 수술
- 화학 치료
- 방사선 치료
- 표적 치료
- 암 면역 치료
- 종양 용해성 바이러스 치료
- 항체 약물 복합체
- Porter's Five Forces 분석
제3장 시장 역학
- 시장 역학
- 시장 성장 촉진요인
- 항암제의 강력한 승인
- 암 치료에 있어서의 기술의 진보
- 암 발병률 증가
- 시장 성장 억제요인
- 독점성의 상실과 일반화
- 종양 전문가의 부족
- 시장 기회
- 종양 부문에서 AI 도입
- 파이프라인 후기 단계에 있는 유망한 의약품
제4장 규제 상황
- 미국 승인 프로세스
- 암 치료제 개발에 관한 FDA 규제 고려 사항
- EU 승인 프로세스
- EU 승인 프로세스의 현상
- 일본 승인 프로세스
제5장 새로운 동향과 파이프라인 분석
- 신흥기술
- 개인화된 암 백신
- 18유형의 조기암을 식별하는 검사
- CAR T 세포 치료
- AI
- 유방암 위험을 줄이는 태블릿
- 나노입자
- 가압 복강 내 에어로졸 화학 치료
- 자궁경부암 치료의 획기적인 진보
- 새로운 전개
- 바이오시밀러의 승인
- 파이프라인 분석
- 임상시험 분석
- 특허 분석
- 중요 포인트
제6장 공급망 분석
- 개요
- 연구개발
- 제조
- 포장
- 도매 유통업체 및 재포장업체
- 약국
- 소비자 유통
- 항암제 부족
- 비용
- 제조의 복잡성
- 지리적 집중도
- 품질
제7장 시장 세분화 분석
- 세분화의 내역
- 시장 분석 : 암 유형별
- 폐암
- 유방암
- 대장암
- 전립선암
- 위암
- 간암
- 자궁경부암
- 방광암
- 신장암
- 췌장암
- 난소암
- 기타
- 지리적 내역
- 시장 분석 : 지역별
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제8장 경쟁 정보
- 개요
- 블록버스터 종양 치료제 브랜드
- 주요 기업의 시장 점유율
제9장 재발 및 전이 부문을 중심으로 한 암 치료제 시장 : 지속가능성과 ESG 관점
- 제약 업계에서 ESG의 역할
- ESG 성능 분석
- 환경 요인
- 사회적 요인
- 거버넌스 요인
- ESG 위험 평가
- 총론
제10장 부록
- 조사 방법
- 신흥 스타트업 기업/시장 파괴자
- 출처
- 약어
- 기업 프로파일
- ABBVIE INC.
- AMGEN INC.
- ASTRAZENECA
- BAYER AG
- BRISTOL-MYERS SQUIBB CO.
- F. HOFFMANN-LA ROCHE LTD.
- GILEAD SCIENCES INC.
- JOHNSON & JOHNSON SERVICES INC.
- LILLY
- MERCK & CO. INC.
- NOVARTIS AG
- PFIZER INC.
- REGENERON PHARMACEUTICALS INC.
- SANOFI
- TAKEDA PHARMACEUTICAL CO. LTD.
KTH
The global market for cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $116.1 billion in 2024 to reach $168.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2029.
The global market for lung cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $16.2 billion in 2024 to reach $29.0 billion by 2029, at a CAGR of 12.4% from 2024 to 2029.
The global market for breast cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $13.7 billion in 2024 to reach $23.6 billion by 2029, at a CAGR of 11.4% from 2024 to 2029.
Report Scope
Both qualitative and quantitative data on the current dynamics impacting the global cancer therapeutics market are presented in this report. It discusses the history of cancer, its different forms, its pathophysiology, its stages of development and its mechanisms of metastasis and recurrence. It also incorporates the disease burden by knowing the epidemiology of different cancers. Treatment patterns that include both non-pharmacological (e.g., radiation, surgery) and pharmacological (e.g., hormonal therapy, targeted therapy, cytotoxic/chemotherapy, combinatorial therapy) approaches are discussed to illustrate the various therapeutic options available to patients.
Analyses of the most popular products, the state of clinical trials and new product approvals are also included in the report. The demographics of the major regions-North America, Europe, Asia-Pacific and the Rest of the World-as well as their prospects for growth, are summarized. The profiles of leading companies and the strategies of international businesses involved in the cancer treatment sector are also discussed.
Estimations of the market size for therapies that treat cancer metastases and recurrence states are included in the scope. Cancer types noted in this report include:
- Lung.
- Breast.
- Liver.
- Stomach.
- Prostate.
- Colorectal.
- Gastric.
- Cervical.
- Bladder.
- Kidney.
- Ovarian.
- Lymphoma.
- Multiple myeloma.
- Brain tumors.
- Thyroid.
- Uterine.
Additional growth potential and forecast data are discussed for the cancer therapeutics market, as well as for the cancer types, regions and countries.
For market estimates, data are provided for 2023 as the base year, with forecasts for the period of 2024 through 2029.
Report Includes
- 51 data tables and 83 additional tables
- An overview of the global market for cancer therapeutics with emphasis on recurrent and metastatic divisions
- Analyses of global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by cancer type and region
- A look at the factors driving the market's growth and constraints
- Insight into the industry value chain analysis, providing a study of the intermediaries involved
- Description of cancer development stages, including the mechanisms of metastasis and recurrences, and the current diagnostics such as medical imaging, in vitro diagnostics technologies and treatment patterns
- Coverage of causes, risk factors, prevalence and incidence of cancer, and information on its economic burden
- Review of pharmacological approaches covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy and combinatorial therapy and non-pharmacological treatments such as surgeries and radiation
- Identification of the fastest-growing applications and technologies, and a review of current market trends
- Discussion of the industry's ESG challenges and practices
- Review of the current market status, technology issues, industry value chain, Porter's Five Forces, competitive landscape, R&D activity and patent analysis
- Assessment of the vendor landscape, including the market shares of leading companies, their product portfolios and financial overviews
- Updates on recent mergers and acquisitions, facility expansions, collaborations, investments, divestments, new products and other strategic developments
- Profiles of the leading vendors, including Merck & Co. Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., and AstraZeneca
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Overview
- Metastatic or Recurrent Cancer Treatment Types
- Surgery
- Chemotherapy
- Radiotherapy
- Targeted Therapy
- Cancer Immunotherapies
- Oncolytic Virotherapy
- Antibody-Drug Conjugates
- Porter's Five Forces Analysis in the Oncology Market
- Potential of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitute Products or Services
- Industry Rivalry: High
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Robust Approval of Oncology Drugs
- Technological Advances in Cancer Treatments
- Increasing Incidence of Cancer Disease
- Market Restraints
- Loss of Exclusivity and Genericization
- Lack of Oncology Professionals
- Market Opportunities
- Incorporation of Artificial Intelligence in Oncology
- Promising Drugs in the Late Stage of the Pipeline
Chapter 4 Regulatory Landscape
- The U.S. Approval Process
- FDA Regulatory Considerations for Oncology Drug Development
- European Union Approval Process
- Current Situation in E.U. Approval Process
- Japanese Approval Process
Chapter 5 Emerging Trends and Pipeline Analysis
- Emerging Technologies
- Personalized Cancer Vaccines
- Test to Identify 18 Early-Stage Cancers
- CAR T-Cell Therapy
- Artificial Intelligence
- Tablet to Cut Breast Cancer Risk
- Nanoparticles
- Pressurized Intraperitoneal Aerosol Chemotherapy
- Cervical Cancer Treatment Breakthrough
- New Developments
- Biosimilar Approvals
- Pipeline Analysis
- Clinical Trial Analysis
- Patent Analysis
- Key Takeaways
Chapter 6 Supply Chain Analysis
- Overview
- Research and Development
- Manufacturing
- Packaging
- Wholesale Distributors and Repackagers
- Pharmacies
- Dispensed to Consumers
- Cancer Drug Shortage
- Costs
- Manufacturing Complexity
- Geographic Concentration
- Quality
Chapter 7 Market Segmentation Analysis
- Segmentation Breakdown
- Market Analysis, by Cancer Type
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Liver Cancer
- Cervix Cancer
- Bladder Cancer
- Kidney Cancer
- Pancreatic Cancer
- Ovarian Cancer
- All Other Cancers
- Geographic Breakdown
- Market Analysis, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 8 Competitive Intelligence
- Overview
- Blockbuster Oncology Pharmaceutical Brands
- Global Market Shares of Leading Companies
Chapter 9 Sustainability in Cancers Therapeutics Market Emphasis on Recurrent and Metastatic Divisions: ESG Perspective
- Role of ESG in the Pharma Industry
- ESG Performance Analysis
- Environmental Factors
- Social Issues
- Governance Factors
- ESG Risk Ratings
- Conclusion
Chapter 10 Appendix
- Methodology
- Emerging Start-ups/Market Disruptors
- Sources
- Abbreviations
- Company Profiles
- ABBVIE INC.
- AMGEN INC.
- ASTRAZENECA
- BAYER AG
- BRISTOL-MYERS SQUIBB CO.
- F. HOFFMANN-LA ROCHE LTD.
- GILEAD SCIENCES INC.
- JOHNSON & JOHNSON SERVICES INC.
- LILLY
- MERCK & CO. INC.
- NOVARTIS AG
- PFIZER INC.
- REGENERON PHARMACEUTICALS INC.
- SANOFI
- TAKEDA PHARMACEUTICAL CO. LTD.
